The application and outlook of proteomics in Ovarian Cancer, Breast Cancer, and Colon Cancer

The Ohio State University, Columbus, Ohio, United States

e-mail: yiruxie025@gmail.com

Abstract

Cancer, a pervasive challenge of global health, necessitates advanced technologies for diagnosticsand therapies. Ovarian, breast, and colon cancers, notable for their complexity, have made significantdiscoveries with the help of proteomics. Ovarian cancer, diagnosed late, benefits from proteomicsbiomarkers like CA-125 and plasma CRP, offering early detection and insights into sub-types. Breast cancerleverages proteomics for sub-type classification, treatment prediction, and liquid biopsy development.Markers like uPA and PAI-1 guide therapies, while phosphorous proteomics unveils crucial signalingpathways. Colon cancer, marked by its prevalence, sees proteomics aiding biomarker discovery, sub-typeclassification, and predicting treatment responses, fostering personalized treatments. Liquid biopsydevelopment holds promise for real-time monitoring. Propelled by advanced technologies like LC-MS/MSand iTRAQ, proteomics provides a holistic view of cancer biology. Integrating with genomics refinesprecision medicine. Insights from proteomics in ovarian, breast, and colon cancers mark a era oftransformation, offering personalized cancer care and improved clinical outcomes.